Forth Cancer screening

TruCheck™ Early Cancer Screening Blood Test

A blood test the provider markets as an early screening check for signals linked to over 70 cancer types, for adults over 35; the exact markers used are not published.

  • Doctor reviewed
Sample
Blood
Collection
Home nurse visit or venous draw at a partner clinic
Doctor reviewed
Yes

Test specifications

Provider
Forth
Sample type
blood
Collection method
home nurse visit or venous draw at a partner clinic
Turnaround time
Not specified
At-home test
No
Doctor reviewed
Yes
Gender focus
Both

About this test

Forth markets this as an early cancer screening blood test for adults over 35, which it says looks for signals linked to more than 70 cancer types, including breast, ovarian, melanoma, liver, lung and prostate cancer, using a blood draw it describes as non-invasive. The provider states the underlying method has been validated on over 40,000 participants. We report these as the provider's own claims; we have not independently verified them, and a result from this test should be discussed with a GP rather than treated as a diagnosis or a reason to rule out further investigation.

There are no directly comparable tests in our data to benchmark this one against, so we cannot say whether £1,169 represents good or poor value relative to peers. What we can say is that Forth does not publish how many biomarkers the test measures, nor a turnaround time, which is unusual among its other tests and limits how much we can independently assess about its depth.

The clinical depth score is low mainly because the marker count is not stated, and our confidence in this score is lower than for Forth's other tests as a result. Collection convenience also scores lower than Forth's other tests, since this is the only one requiring a nurse visit or a clinic-based venous draw, with no at-home self-collection option. Results are still reviewed by a doctor.

Who is it for?

Given the price and the limited published detail on what exactly is measured, this is worth approaching carefully. If you are considering it, ask Forth directly how many and which biomarkers are included and what the turnaround time is before paying £1,169. For a general, transparent health check with a published marker list, Forth's own Ultimate Health Check (£399, 47 markers) may be a more informative starting point, and any specific symptoms or concerns about cancer risk should be discussed with a GP.

How it works

You provide a sample via a home nurse visit or a venous draw at a partner clinic; there is no self-collection option for this test. Forth states the sample is analysed for signals linked to a wide range of cancer types, though it does not publish the number of markers involved or a turnaround time. A doctor reviews the results before they are released to you.

Pros & cons

Pros

  • Includes a doctor review of results, as with Forth's other tests.
  • Sample can be collected via a home nurse visit rather than only at a clinic.

Cons

  • The provider does not state how many biomarkers the test measures.
  • No turnaround time is published.
  • At £1,169, there are no comparable tests in our data to check whether this represents good value.
  • No at-home self-collection option; requires a nurse visit or clinic draw.

Our editorial score

Compare Health Test Score £1,169 multi-cancer screen with no published marker count
Editorial confidence: 7.0/10

Score breakdown

  • Clarity and documentation 5.0/10

    The listing publishes a short description, clear collection options, the sample type; it does not state the biomarkers measured, a turnaround time, what the report looks like.

  • Clinical depth 3.5/10

    The provider does not state how many biomarkers are measured, so depth cannot be assessed.

  • Collection convenience 4.0/10

    Requires a venous draw at a clinic; a home nurse visit is offered.

  • Results and follow-up 7.0/10

    Results are reviewed by a doctor.

  • Trust signals 8.5/10

    Trustpilot 4.2 from 1,727 reviews; accredited lab (UKAS ISO 15189 partner labs); doctor review as standard; trading 10+ years.

  • Value for money 6.0/10

    £1,169.00; no comparable tests to benchmark against yet.

More in Cancer screening

View all →
Selph

qFIT Bowel Cancer Screening Test

A stool test using the qFIT method to measure blood in a stool sample, giving a numerical result rather than a simple positive or negative. Suited to adults wanting to check a common early indicator of possible bowel cancer risk.

  • At-home test
8.1 / 10 Priced close to the FIT test group median
£59.00
Full review →